Clinical Trials
170 trialsVenetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Dana-Farber Cancer Institute
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
CAVALRY
University of Chicago
HeartPhone Cancer Survivors Trial 2019
Penn State University
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
City of Hope Medical Center
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
EBNK-ST-001
Essen Biotech
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Dana-Farber Cancer Institute
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Seattle Children's Hospital
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
PACMAN
Princess Maxima Center for Pediatric Oncology
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Assiut University
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ain Shams University
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
GL-CLB-001
Jewish General Hospital
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
STP-LYM-01
Technical University of Munich
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
H. Lee Moffitt Cancer Center and Research Institute
UF-AML-CE-101
University of Florida
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
CAR-T
Shenzhen University General Hospital
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Banc de Sang i Teixits
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
Shanghai Jiao Tong University School of Medicine
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center